These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33499047)

  • 1. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells.
    El Hallal R; Lyu N; Wang Y
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR Downregulation after Anti-EGFR Therapy Predicts the Antitumor Effect in Colorectal Cancer.
    Okada Y; Kimura T; Nakagawa T; Okamoto K; Fukuya A; Goji T; Fujimoto S; Sogabe M; Miyamoto H; Muguruma N; Tsuji Y; Okahisa T; Takayama T
    Mol Cancer Res; 2017 Oct; 15(10):1445-1454. PubMed ID: 28698359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
    Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
    Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel epithelial cell adhesion molecule antibody conjugated polyethyleneimine-capped gold nanoparticles for enhanced and targeted small interfering RNA delivery to retinoblastoma cells.
    Mitra M; Kandalam M; Rangasamy J; Shankar B; Maheswari UK; Swaminathan S; Krishnakumar S
    Mol Vis; 2013; 19():1029-38. PubMed ID: 23687439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells.
    Rodrigues JG; Duarte HO; Gomes C; Balmaña M; Martins ÁM; Hensbergen PJ; de Ru AH; Lima J; Albergaria A; van Veelen PA; Wuhrer M; Gomes J; Reis CA
    Cell Oncol (Dordr); 2021 Aug; 44(4):835-850. PubMed ID: 33847896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
    Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
    PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gold nanoparticles affect the antioxidant status in selected normal human cells.
    Daems N; Penninckx S; Nelissen I; Van Hoecke K; Cardinaels T; Baatout S; Michiels C; Lucas S; Aerts A
    Int J Nanomedicine; 2019; 14():4991-5015. PubMed ID: 31371943
    [No Abstract]   [Full Text] [Related]  

  • 8. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice.
    Karmani L; Labar D; Valembois V; Bouchat V; Nagaswaran PG; Bol A; Gillart J; Levêque P; Bouzin C; Bonifazi D; Michiels C; Feron O; Grégoire V; Lucas S; Vander Borght T; Gallez B
    Contrast Media Mol Imaging; 2013; 8(5):402-8. PubMed ID: 23740810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model.
    Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin WJ; Chen FD; Lin MH; Wang HE
    Nanotechnology; 2014 Jul; 25(29):295102. PubMed ID: 24990295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SERS characterization of colorectal cancer cell surface markers upon anti-EGFR treatment.
    Lyu N; Pedersen B; Shklovskaya E; Rizos H; Molloy MP; Wang Y
    Exploration (Beijing); 2022 Jun; 2(3):20210176. PubMed ID: 37323700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gold Nanoparticles Enhance EGFR Inhibition and Irradiation Effects in Head and Neck Squamous Carcinoma Cells.
    Kashin M; Kakei Y; Teraoka S; Hasegawa T; Yamaguchi A; Fukuoka T; Sasaki R; Akashi M
    Biomed Res Int; 2020; 2020():1281645. PubMed ID: 33204681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
    Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
    Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.
    Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H
    Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Where now for anti-EGF receptor therapies in colorectal cancer?
    Shaw PH; Adams RA
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1543-53. PubMed ID: 21999128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
    Chen SH; Tsai HL; Jiang JK; Sung YC; Huang CW; Yeh YM; Chen LT; Wang JY
    BMC Cancer; 2019 Jun; 19(1):640. PubMed ID: 31253124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterising the phenotypic evolution of circulating tumour cells during treatment.
    Tsao SC; Wang J; Wang Y; Behren A; Cebon J; Trau M
    Nat Commun; 2018 Apr; 9(1):1482. PubMed ID: 29662054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.